+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

TCR Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

TCR Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 280 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 80 Pages
  • Global
From
Thyroid Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Thyroid Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 180 Pages
  • Global
From
Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • July 2024
  • 240 Pages
  • Global
From
Biliary Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • July 2024
  • 180 Pages
  • Global
From
Advanced liver cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced liver cancer - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 180 Pages
  • Global
From
From
Gastric Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 550 Pages
  • Global
From
Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 150 Pages
  • Global
From
Urothelial Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Urothelial Carcinoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 170 Pages
  • Global
From
Metastatic Liver Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Liver Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Medullary Thyroid Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Medullary Thyroid Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Vulvar Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Vulvar Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
Chondrosarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Chondrosarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Gallbladder Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Gallbladder Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Clear Cell Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Clear Cell Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Anaplastic Thyroid Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Anaplastic Thyroid Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more